Merck KGaA posts strong organic performance of healthcare

9 November 2023

German pharma, science and technology company Merck KGaA (MRK: DE) today confirmed its forecast for fiscal 2023 despite a difficult market environment in the third quarter. Merck’s shares were up 5.6% at 156.30 euros following the announcement.

Group net sales decreased organically by 4.1% to 5,173 million euros ($5.54 billion) in the third quarter of 2023. While Healthcare delivered an organic sales increase of 7.4%, Life Science and Electronics recorded organic sales declines.

Despite the organic earnings growth of 17.2% in the Healthcare business sector, group earnings before interest, tax, depreciation and amortization (EBITDA) pre decreased organically by 13.2% to 1,446 million euros, slightly ahead of an average analyst estimate of 1.39 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK